NCT05754996View on ClinicalTrials.gov

Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 12, 2023

Primary Completion Date

July 29, 2025

Study Completion Date

July 29, 2025

Conditions
Hepatic Encephalopathy
Interventions
DRUG

Nifuroxazide

Nifuroxazide dosing : 200 mg capsule four times daily

DRUG

Lactulose

Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools

DRUG

Rifaximin 550Mg Tab

Rifaximin 550 MG twice daily

Trial Locations (1)

Unknown

National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo

All Listed Sponsors
lead

Cairo University

OTHER